IRX Therapeutics Inc. has appointed biotech industry veterans Mark Leuchtenberger and Monil Shah to president, CEO and director, and as chief operating officer, respectively. IRX’s founder and prior CEO, John W. Hadden, will continue at the company as a director. Leuchtenberger was president, CEO and member of the board at Chiasma Inc., Acusphere Inc. and Rib-X Pharmaceuticals Inc. (now Melinta Therapeutics Inc.). He has also been president and CEO of Targanta Therapeutics Corp. and Therion Biologics Corp. Before this, he was senior officer at Biogen Inc. and co-founded Albor Biologics Inc. and Alvos Therapeutics Inc. Shah brings more than 17 years of pharma and biotech experience in oncology to IRX; most recently, he was medical affairs lead for immuno-oncology at Bristol-Myers Squibb Co. He started his career at Novartis AG in the oncology early development group, and later co-founded Ventrus Biosciences as head of clinical operations and development.
Rare genetic diseases focused Therachon SAS has appointed as chief medical officer Maarten Kraan, AstraZeneca PLC‘s former vice president, head of innovative medicines and respiratory and inflammation. Before AstraZeneca, Kraan was vice president, head of clinical research and experimental development inflammation at Hoffmann-La Roche Inc